Overview

Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes

Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
This is a multi-centre, open-label, randomized, parallel trial to compare the effect of Exenatide versus Biphasic insulin Aspart 30 on glucose variability and inflammatory markers in type 2 diabetes mellitus (T2DM) patients inadequately controlled with metformin monotherapy.
Phase:
Phase 4
Details
Lead Sponsor:
Xijing Hospital
Collaborators:
Air Force Military Medical University, China
Chang An Hospital
Chang'An Hospital
First Affiliated Hospital Xi'an Jiaotong University
Fourth Military Medical University
Second Affiliated Hospital of Xi'an Jiaotong University
Shaanxi Aerospace Hospital
Shaanxi Provincial People's Hospital
Xi'an Central Hospital
Xi'an Gaoxin Hospital
Xi’an Gaoxin Hospital
Treatments:
Biphasic Insulins
Exenatide
Insulin
Insulin Aspart
Insulin aspart, insulin aspart protamine drug combination 30:70
Insulin degludec, insulin aspart drug combination
Insulin, Globin Zinc
Insulin, Isophane
Insulin, Long-Acting